Osilodrostat for Cushing's Syndrome

(LINC CARE Trial)

This trial aims to test osilodrostat, a treatment for people with Cushing's Syndrome, which causes excessive cortisol (a stress hormone) in the body. Researchers seek to determine its effectiveness in lowering cortisol levels, particularly in individuals with poorly controlled high blood pressure. Participants should have Cushing's Syndrome and high blood pressure despite medication. As a Phase 4 trial, this research helps clarify how the already FDA-approved and effective treatment benefits a broader range of patients.

Research has shown that osilodrostat is generally safe for people with Cushing's syndrome. In studies involving over 200 patients, osilodrostat effectively controlled symptoms, and its side effects were manageable. Most participants found the treatment easy to handle, with side effects typically ranging from mild to moderate.

The FDA has approved osilodrostat for treating Cushing's syndrome, indicating thorough testing and proven safety for this condition. Some individuals experienced side effects like nausea or tiredness, but these were not severe for most.

Unlike the standard treatments for Cushing's Syndrome, which often include medications like ketoconazole, metyrapone, or mitotane, osilodrostat offers a fresh approach. It works by specifically inhibiting an enzyme called 11β-hydroxylase, crucial for cortisol production, directly targeting the source of the problem. This targeted mechanism can result in more precise cortisol control, potentially reducing side effects associated with broader-acting medications. Researchers are excited about osilodrostat because it promises a more refined and potentially more effective treatment strategy for those struggling with this challenging condition.

Research has shown that osilodrostat, which participants in this trial may receive, effectively lowers cortisol levels in people with Cushing's syndrome. In studies, 72.4% of patients achieved normal cortisol levels, which is crucial for managing this condition. Patients also experienced improvements in blood pressure and blood sugar levels, common issues in Cushing's syndrome. Additionally, 89.5% of patients had reduced cortisol levels in their urine, confirming the treatment's effectiveness. Overall, osilodrostat has proven to be both effective and safe for long-term use in treating Cushing's syndrome.⁶⁷⁸⁹¹⁰